Chief Medical Officer
Dr. Kali Stasi was appointed Chief Medical Officer of SparingVision in June 2025.
Kali (Kalliopi) drives the clinical strategy for the advancement of SparingVision’s portfolio of platform-in-a-product programs through proof of concept, pivotal trials and towards commercialization. She also leads medical affairs and patient advocacy.
Previously, Kali held several clinical leadership positions at Diorasis Therapeutics, SalioGen Therapeutics, Tenpoint Therapeutics and Adverum Biotechnologies where she oversaw three active Phase I & II clinical trials and preparing for two Phase III clinical trials in wet AMD. Prior to this, she held the role of Translational Medicine Director for Ophthalmology for Novartis Institutes for Biomedical Research (NIBR), where she notably led the successful RLBP1 inherited retina dystrophy program and co-led the ex-US launch of Luxturna®, the only gene therapy approved to date in ophthalmology.
Kali is an ophthalmologist, holds an M.D. and Ph.D. from the University of Patra, School of Medicine in Greece, was assistant professor at University of Pennsylania, and has trained at leading academic institutions including Harvard Medical School, Mount Sinai, the University of Rochester, Wharton Business School and Johns Hopkins. She is the recipient of the Novartis Ophthalmology Vision Award and has authored numerous peer-reviewed publications.